FDA Recall of LeadCare II Blood Lead Test Kits
Magellan Diagnostics, Inc. is recalling 197,893 units of LeadCare II Blood Lead Test Kits due to reports of unexpectedly elevated results from certain third-party devices.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on May 7, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — FDA Recalls — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, Devices) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What Happened
Magellan Diagnostics, Inc. is recalling the LeadCare II Blood Lead Test Kits because customers reported observing unexpectedly elevated results when using certain third-party micro-collection devices for testing. This issue may lead to false positive lead results, causing delayed results and additional unnecessary testing.
Which Products Are Affected
The affected products are: (1) LeadCare II Blood Lead Test Kit with Catalog Number 70-6762, (2) LeadCare II 5X Blood Lead Test Kit with Catalog Number 70-8404 (Box containing 5 Test Kits), (3) LeadCare II 9X Blood Lead Test Kit with Catalog Number 70-9000 (Box containing 9 test kits), and (4) LeadCare II 5X Blood Lead Test Kit with Catalog Number 70-6762RUO. The kits include UDI-DI codes: 00850355006000 for Catalog Numbers 70-6762 and 70-6762RUO, 00850355006086 for 70-8404, and 00850355006093 for 70-9000. All lots and sublots are affected, with a total of 197,893 units distributed worldwide, including US Nationwide and countries such as Argentina, Australia, and Canada. The recall was initiated on March 13, 2026, under recall number Z-1893-2026.
What You Should Do
Consumers should stop using the affected LeadCare II Blood Lead Test Kits immediately and contact Magellan Diagnostics, Inc. at their address: 101 Billerica Ave Bldg 4, North Billerica, MA 01862-1271, as the initial notification was made via letter. Follow the firm's instructions for returns or refunds, and refer to the recall number Z-1893-2026 for more details.
Why This Matters
This recall affects blood lead testing accuracy, potentially leading to unnecessary medical testing and delays in proper diagnosis for users worldwide. It highlights the importance of reliable diagnostic devices in healthcare to ensure patient safety and accurate results.
Source
This information is from the FDA recall database, attributed to recall number Z-1893-2026 on the FDA website.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.